Tempus AI Inc (TEM)

Tempus AI applies artificial intelligence to clinical and molecular data with the goal of making precision medicine actionable at the point of care. The company sequences tumor genomes, structures electronic health records, digitizes pathology slides, and feeds all of it into machine-learning pipelines that surface treatment-relevant patterns for oncologists and their patients. A parallel data-licensing business lets pharmaceutical companies mine de-identified datasets for biomarker discovery, clinical-trial design, and real-world evidence generation. Headquarters are in Chicago, with laboratory and engineering operations across the United States. Tempus has assembled one of the largest clinically annotated datasets in oncology by partnering with health systems that contribute longitudinal patient records in exchange for analytic tools and sequencing services.